Apoptogen, Inc.

Dianovix, Inc.

University of Ottawa

Aegera Therapeutics, Inc.

Martin Holcik

Robert G Korneluk

Peter Liston

Stephen Baird

George S Robertson

Eric LaCasse

Virender Bhan

Sean Young

Andrea Hebb

John W Gillard

Craig Moore

Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.

Diagnostic marker for interferon responsiveness in multiple sclerosis

Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.

Method for differentiating between multiple sclerosis subtypes

The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

Antisense IAP oligonucleotides and uses thereof

The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

Antisense IAP nucleic acids and uses thereof

The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.

XIAP IRES and uses thereof

Growing community of inventors

Ottawa, Canada

Martin Holcik